UroNexis

ONCOLOGY

NON-CONFIDENTIAL INVESTMENT OVERVIEW

Restoring PDE4D7 in prostate cancer

Locally delivered AAV gene therapy for primary, localised prostate cancer, with an initial focus on high-risk disease.

GOI AND THERAPEUTIC CASSETTE LOCKED

The PDE4D7 gene of interest (GOI) and expression cassette are locked. AAV serotypes are being evaluated in vitro and in vivo to select the capsid and final product configuration.

We expect to nominate our development candidate in late Q4 2026 or early Q1 2027.

FINANCING TARGET

€7-8M

Seed / pre-Series A

For the development package targeting clinical trial authorisation/notification (CTA/CTN) readiness in Q4 2028 or Q1 2029.

THE INVESTMENT OPPORTUNITY

More than 15 years of Philips-supported research underpin a biomarker-informed programme in high-risk prostate cancer. Cellular restoration studies and exploratory models support the therapeutic rationale.

Local delivery aims to concentrate treatment in the prostate. Lower vector requirements could improve tolerability and reduce manufacturing costs per treatment.

WHAT THE ROUND FUNDS

Candidate development. Selection, confirmatory proof-of-concept and biodistribution.

CMC and supply. Manufacturing process, assays, formulation and material supply.

Safety package. Pilot/dose-range and GLP toxicology studies.

Clinical readiness. Clinical/regulatory preparation and lean company operations.

VALUE-CREATING MILESTONES

The round advances the programme from candidate nomination through a defined safety and manufacturing package. Pilot/dose-range safety work is targeted for completion by Q1 2028, followed by formal GLP studies and the CTA/CTN readiness package.

FUNDING STRATEGY

BII: a separate DKK 4M funding target, excluded from the €7-8M target; not yet awarded. A subsequent Series A would fund clinical trial execution, additional GMP scale-up and clinical supply. We welcome specialist biotech investors, angels and strategic partners.

UroNexis is in exclusive licensing discussions with Philips; definitive rights and terms remain to be agreed. Financing and timelines are targets; budget scope is being refined against supplier quotes, regulatory feedback and licence terms.

Ralf Hoffmann, CSO · Morten Fjordholt, CEO · Frédéric Guillanneuf, CBO

Investment enquiries: morten.fjordholt@uronexisoncology.com

UroNexisOncology.com